Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07204327
Active, not recruiting Observational

Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)

NCT07204327 · tracked via the Priya Life Science China tracker
Sponsor
Zhongda Hospital
Phase
Observational
Started
2020-10-28
Last updated
2025-10-02

Condition(s) studied

Unresectable Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

Atezo+Bev plus Locoregional Therapy

Atezo+Bev plus Locoregional Therapy: Patients received atezolizumab plus bevacizumab (Atezo+Bev) in combination with at least one locoregional therapy (transarterial chemoembolization \[TACE\], hepatic arterial infusion chemotherapy \[HAIC\], transarterial radioembolization \[TARE\], ablation, or radiotherapy) within ±2 months of systemic therapy initiation, in routine clinical practice.

Study summary

This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), transarterial radioembolization (TARE), ablation, and radiotherapy, in patients with unresectable hepatocellular carcinoma (uHCC). Approximately 1,136 patients treated between October 28, 2020 and October 31, 2025 will be included from about 35 sites across China and the Asia-Pacific region. The primary endpoint is overall survival (OS). Secondary endpoints include real-world progression-free survival (rwPFS), overall response rate (ORR), disease control rate (DCR), time to discontinuation (TTD), time to next treatment (TTNT), time to progression (TTP), and safety outcomes. Exploratory analyses will assess associations between baseline patient characteristics, treatment patterns, and clinical outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years at initiation of atezolizumab plus bevacizumab (Atezo+Bev) * Histologically or radiologically confirmed unresectable hepatocellular carcinoma (uHCC) according to national guidelines * Initiated first-line Atezo+Bev treatment between October 28, 2020 and July 31, 2025 * Received ≥1 locoregional therapy (TACE, HAIC, TARE, ablation, or radiotherapy) within ±2 months of Atezo+Bev initiation * At least one follow-up record available after treatment initiation Exclusion Criteria: * Prior systemic therapy for HCC before Atezo+Bev initiation * Concurrent participation in interventional clinical trials at baseline * Diagnosis of other malignancies at baseline (except basal cell carcinoma of the skin)

Primary outcome measure(s)

  • Overall Survival (OS) — Up to 36 months (median follow-up period anticipated)
    Overall survival, defined as the time from initiation of atezolizumab plus bevacizumab treatment to death from any cause.

Trial sites (1)

FacilityCityRegionStatus
Zhongda Hospital, Southeast University Nanjing Jiangsu

More Zhongda Hospital trials in China

Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability Recruiting
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection Starting soon
Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability Recruiting
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease Starting soon
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma Recruiting

Other trials for the same condition

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC Recruiting
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study Recruiting
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere Active, not recruiting
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer Active, not recruiting
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07204327 on ClinicalTrials.gov ↗ ← All trials in China